Friday, November 22, 2024
FGF
FGF
FGF

Combating most cancers with nanoparticles

In keeping with the European Fee, most cancers is on the rise within the EU, with the variety of new circumstances reaching 2.7 million in 2022. Most cancers deaths for that very same 12 months additionally went up and had been estimated to be at 1.3 million.

Combating most cancers with nanoparticles

Specifically, pancreatic most cancers remained the main reason behind cancer-related deaths within the EU in 2022. Though this most cancers has a decrease incidence than many others (it ranks 8th amongst males and 5th amongst girls), its low survival price locations it among the many prime 4 deadliest cancers in each women and men.

Since 2020, the ULISES Consortium has been working laborious to develop a brand new remedy to struggle pancreatic most cancers by means of nanoparticles. The main focus of this venture is to get a affected person’s immune system to reject the tumor. Its modern technique primarily consists of delivering genetic materials to the tumor cells to make them seen to the immune system, thus triggering a response akin to the vaccine impact. Nanoparticles play a vital function on this. As soon as synthesized, they bear a hanging resemblance to these used for the COVID-19 vaccine. As solely tumor cells are focused, this new remedy would additionally keep away from many of the opposed reactions of present therapies, comparable to chemo- and radiotherapy.

Furthermore, if this remedy proves efficient, it will not solely present a treatment for one of many deadliest cancers on this planet, pancreatic most cancers but additionally open up a brand new therapeutic alternative for different sorts of lethal tumors that at the moment haven’t any treatment choices.

To be taught extra in regards to the venture, watch our Video Information Launch.

Nanoparticles and main improvements: preventing most cancers by means of the immune system

This Video Information Launch was produced by Diego Giuliani, ICONS editorial supervisor

Related Articles

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest Articles